Metal ions, Alzheimer's disease and chelation therapy
Identifieur interne : 002115 ( Main/Corpus ); précédent : 002114; suivant : 002116Metal ions, Alzheimer's disease and chelation therapy
Auteurs : Ana BudimirSource :
- Acta Pharmaceutica [ 1330-0075 ] ; 2011-03-01.
English descriptors
Abstract
In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Url:
DOI: 10.2478/v10007-011-0006-6
Links to Exploration step
ISTEX:4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metal ions, Alzheimer's disease and chelation therapy</title><author wicri:is="90%"><name sortKey="Budimir, Ana" sort="Budimir, Ana" uniqKey="Budimir A" first="Ana" last="Budimir">Ana Budimir</name><affiliation><mods:affiliation>Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C</idno><date when="2011-03-15" year="2011">2011-03-15</date><idno type="doi">10.2478/v10007-011-0006-6</idno><idno type="url">https://api.istex.fr/document/4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002115</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Metal ions, Alzheimer's disease and chelation therapy</title><author wicri:is="90%"><name sortKey="Budimir, Ana" sort="Budimir, Ana" uniqKey="Budimir A" first="Ana" last="Budimir">Ana Budimir</name><affiliation><mods:affiliation>Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Pharmaceutica</title><idno type="ISSN">1330-0075</idno><idno type="eISSN">1846-9558</idno><imprint><publisher>Versita</publisher><date type="published" when="2011-03-01">2011-03-01</date><biblScope unit="volume">61</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="14">14</biblScope></imprint><idno type="ISSN">1330-0075</idno></series><idno type="istex">4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C</idno><idno type="DOI">10.2478/v10007-011-0006-6</idno><idno type="ArticleID">v10007-011-0006-6</idno><idno type="Related-article-Href">v10007-011-0006-6.pdf</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1330-0075</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer's disease</term><term>chelation therapy</term><term>metal chelators</term><term>metal ions</term><term>neurodegeneration</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.</div></front></TEI><istex><corpusName>degruyter-journals</corpusName><author><json:item><name>Ana Budimir</name><affiliations><json:string>Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>metal ions</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Alzheimer's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurodegeneration</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>metal chelators</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>chelation therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>kovinski ioni</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Alzheimerova bolest</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurodegeneracija</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>kovinski kelatori</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>kelacijska terapija</value></json:item></subject><genre><json:string>research-article</json:string></genre><host><volume>61</volume><pages><last>14</last><first>1</first></pages><issn><json:string>1330-0075</json:string></issn><issue>1</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1846-9558</json:string></eissn><title>Acta Pharmaceutica</title></host><language><json:string>eng</json:string></language><qualityIndicators><score>6.572</score><pdfVersion>1.3</pdfVersion><pdfPageSize>482 x 680 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>10</keywordCount><abstractCharCount>942</abstractCharCount><pdfWordCount>6075</pdfWordCount><pdfCharCount>37875</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>131</abstractWordCount></qualityIndicators><title>Metal ions, Alzheimer's disease and chelation therapy</title><publicationDate>2011</publicationDate><doi><json:string>10.2478/v10007-011-0006-6</json:string></doi><id>4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Metal ions, Alzheimer's disease and chelation therapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Versita</publisher><availability><p>De Gruyter</p></availability><date>2011-03-15</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Metal ions, Alzheimer's disease and chelation therapy</title><author><persName><forename type="first">Ana</forename><surname>Budimir</surname></persName><affiliation>Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia</affiliation></author></analytic><monogr><title level="j">Acta Pharmaceutica</title><idno type="pISSN">1330-0075</idno><idno type="eISSN">1846-9558</idno><imprint><publisher>Versita</publisher><date type="published" when="2011-03-01"></date><biblScope unit="volume">61</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="14">14</biblScope></imprint></monogr><idno type="istex">4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C</idno><idno type="DOI">10.2478/v10007-011-0006-6</idno><idno type="ArticleID">v10007-011-0006-6</idno><idno type="Related-article-Href">v10007-011-0006-6.pdf</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011-03-15</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.</p></abstract><abstract xml:lang="hr"><p>Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>metal ions</term></item><item><term>Alzheimer's disease</term></item><item><term>neurodegeneration</term></item><item><term>metal chelators</term></item><item><term>chelation therapy</term></item></list></keywords></textClass><textClass xml:lang="hr"><keywords scheme="keyword"><list><head>Keywords</head><item><term>kovinski ioni</term></item><item><term>Alzheimerova bolest</term></item><item><term>neurodegeneracija</term></item><item><term>kovinski kelatori</term></item><item><term>kelacijska terapija</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-03-15">Created</change><change when="2011-03-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus degruyter-journals" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" URI="journalpublishing3.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" dtd-version="3.0" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">ACPH</journal-id><journal-title-group><abbrev-journal-title abbrev-type="full">Acta Pharmaceutica</abbrev-journal-title></journal-title-group><issn pub-type="epub">1846-9558</issn><issn pub-type="ppub">1330-0075</issn><publisher><publisher-name>Versita</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v10007-011-0006-6</article-id><article-id pub-id-type="doi">10.2478/v10007-011-0006-6</article-id><title-group><article-title>Metal ions, Alzheimer's disease and chelation therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Budimir</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><aff id="A1">Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia<sup>1</sup></aff></contrib-group><author-notes><corresp></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>15</day><month>3</month><year>2011</year></pub-date><volume>61</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><permissions><license license-type="open-access"><license-p>This content is open access.</license-p></license></permissions><related-article related-article-type="pdf" xlink:href="v10007-011-0006-6.pdf"></related-article><abstract xml:lang="en"><title>Metal ions, Alzheimer's disease and chelation therapy</title><p>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.</p></abstract><abstract xml:lang="hr"><title>Kovinski ioni, Alzheimerova bolest i kelacijska terapija</title><p>Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>metal ions</kwd><kwd>Alzheimer's disease</kwd><kwd>neurodegeneration</kwd><kwd>metal chelators</kwd><kwd>chelation therapy</kwd></kwd-group><kwd-group xml:lang="hr"><title>Keywords</title><kwd>kovinski ioni</kwd><kwd>Alzheimerova bolest</kwd><kwd>neurodegeneracija</kwd><kwd>kovinski kelatori</kwd><kwd>kelacijska terapija</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Metal ions, Alzheimer's disease and chelation therapy</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Metal ions, Alzheimer's disease and chelation therapy</title></titleInfo><name type="personal"><namePart type="given">Ana</namePart><namePart type="family">Budimir</namePart><affiliation>Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia</affiliation></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>Versita</publisher><dateIssued encoding="w3cdtf">2011-03-01</dateIssued><dateCreated encoding="w3cdtf">2011-03-15</dateCreated></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.</abstract><abstract lang="hr">Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</abstract><subject lang="en"><genre>Keywords</genre><topic>metal ions</topic><topic>Alzheimer's disease</topic><topic>neurodegeneration</topic><topic>metal chelators</topic><topic>chelation therapy</topic></subject><subject lang="hr"><genre>Keywords</genre><topic>kovinski ioni</topic><topic>Alzheimerova bolest</topic><topic>neurodegeneracija</topic><topic>kovinski kelatori</topic><topic>kelacijska terapija</topic></subject><relatedItem type="host"><titleInfo><title>Acta Pharmaceutica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1330-0075</identifier><identifier type="eISSN">1846-9558</identifier><identifier type="PublisherID">ACPH</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>14</end></extent></part></relatedItem><relatedItem type="reviewOf"><genre>pdf</genre><identifier type="pdf">v10007-011-0006-6.pdf</identifier></relatedItem><identifier type="istex">4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C</identifier><identifier type="DOI">10.2478/v10007-011-0006-6</identifier><identifier type="ArticleID">v10007-011-0006-6</identifier><identifier type="Related-article-Href">v10007-011-0006-6.pdf</identifier><accessCondition type="use and reproduction" contentType="open-access">This content is open access.</accessCondition><recordInfo><recordContentSource>De Gruyter</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002115 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002115 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:4C02DB8310C7E2C698C17FB8C2CDFFEF93DDC89C
|texte= Metal ions, Alzheimer's disease and chelation therapy
}}
| This area was generated with Dilib version V0.6.23. |  |